Regeneron assumes no responsibility for the User Content on the page, nor for any error, defamation, libel, slander, omission falsehood, obscenity, pornography, profanity, danger or inaccuracy contained in any User Content.

You understand and agree that User Content will be treated as non-confidential and non-proprietary and you are giving us and our affiliates, a royalty-free, irrevocable, perpetual, non-exclusive and fully sublicensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such User Content in whole or in part, on a worldwide basis, and to incorporate them in other works, in any form, media, technology, or products now known or later developed, including for promotional or marketing purposes; and you further represent, warrant, and covenant that you have and will continue to have the legal right to grant these rights.

Please read Facebook's Statements of Rights and Responsibilities for more information.

Adverse Events
This page is not the best place to discuss safety issues or side effects associated with our products or other company’s products. If you, or someone you know, may have possibly experienced a side effect while taking a Regeneron product please contact our Medical Information Department at 1-855-REGEN-4-U (1-855-734-3648) for further information. You can also report any adverse event directly to your healthcare provider or to the U.S. Food and Drug Administration (FDA) by calling 1-800-FDA-1088 or visiting http://www.fda.gov/Safety/MedWatch.">
Regeneron
Edit

Regeneron

https://www.regeneron.com/
Last activity: 18.08.2026
Active
Categories: BiotechGeneticsImmunologyOncologyPharmaceuticals
Please visit www.Regeneron.com/social-media-terms for more information on how to engage with Regeneron on social media.

Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. We do not interview candidates on Google Hangouts. Any questions about job listings can be directed to candidatesupport@regeneron.com.

Regeneron is a leading science and technology company delivering life-transforming medicines for serious diseases. Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including ophthalmology, asthma, atopic dermatitis, pain, cancer and infectious diseases. In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human genetics sequencing efforts in the world and rapid response technologies being used for global good.

Milestones
1988: Regeneron is founded by Leonard S. Schleifer, MD, PhD, young neurologist and assistant professor at Cornell University Medical College. Learn more about our history and milestones here:
https://www.regeneron.com/history

Commenting Guidelines
Thank you for visiting our page. This is a place where we hope you will engage with and learn more about our company and take part in open dialogue that respects other members. We want to hear from you and we’ll respond to your comments and questions as soon as possible.

We respect your right to voice your opinions, but we reserve the right to remove any comments that are considered inappropriate, off-topic, or abusive.
Please don’t use this page to solicit for third-party sites or products.

Comments that are factually inaccurate or misleading, violate another's copyright or intellectual property, use profanity or are defamatory will be deleted.

The content you read here may contain information related to health, medical and fitness conditions and treatment. It is for informational purposes only and not a substitute for professional medical advice, diagnosis, or treatment. Please always consult your doctor.

All comments, visuals, videos and other type of material posted by fans on this site ("User Content") do not necessarily reflect the opinions or ideals of Regeneron, its employees or affiliates.
Regeneron assumes no responsibility for the User Content on the page, nor for any error, defamation, libel, slander, omission falsehood, obscenity, pornography, profanity, danger or inaccuracy contained in any User Content.

You understand and agree that User Content will be treated as non-confidential and non-proprietary and you are giving us and our affiliates, a royalty-free, irrevocable, perpetual, non-exclusive and fully sublicensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such User Content in whole or in part, on a worldwide basis, and to incorporate them in other works, in any form, media, technology, or products now known or later developed, including for promotional or marketing purposes; and you further represent, warrant, and covenant that you have and will continue to have the legal right to grant these rights.

Please read Facebook's Statements of Rights and Responsibilities for more information.

Adverse Events
This page is not the best place to discuss safety issues or side effects associated with our products or other company’s products. If you, or someone you know, may have possibly experienced a side effect while taking a Regeneron product please contact our Medical Information Department at 1-855-REGEN-4-U (1-855-734-3648) for further information. You can also report any adverse event directly to your healthcare provider or to the U.S. Food and Drug Administration (FDA) by calling 1-800-FDA-1088 or visiting http://www.fda.gov/Safety/MedWatch.
Likes
14.8K
Followers
305.37K
Website visits
153K /mo.
Mentions
399
Location: United States
Employees: 10001+
Phone: +1 914-847-7000
Founded date: 1988

Investors 2

Mentions in press and media 399

DateTitleDescription
18.08.2026China's Betta Pharma Hits Limit-Down After Duravyu Fails to Match Rival Eye Drug(Yicai) Aug. 18 -- Shares of China's Betta Pharmaceuticals plunged by the daily limit today after its US partner EyePoint said a late-stage trial of their jointly developed eye disease drug Duravyu failed to show it worked at least as well ...
16.08.2026Infinimmune Secures $75M to Propel Human Antibody TherapeuticsInfinimmune secures $75 million in Series A funding. This capital fuels the company's human-first antibody pipeline. Lead candidates target atopic dermatitis. Clinical trials for these programs are expected in 2027. Regeneron Ventures and P...
12.08.2026Infinimmune Raises $75M in Series A FundingInfinimmune, an Alameda, CA-based biotechnology company developing antibody therapeutics derived directly from the human immune system, raised $75M in Series A funding. The round was co-led by Regeneron Ventures and Playground Global with p...
11.08.2026Quantified Named One of the Fastest-Growing AI & Data Companies on the Inc. 5000 List for the Second Consecutive YearFor the second consecutive year, Quantified lands on the Inc. 5000 list, fueled by growing adoption among top global pharma companies looking to keep commercial teams compliant, certified, coached, and ready to perform. AUSTIN, Texas, Aug. ...
11.08.2026Infinimmune Raises $75M To Advance Human Antibody PipelineInfinimmune Raises $75M For Clinical Development Infinimmune has raised $75 million in Series A funding to advance its antibody therapeutics pipeline. The financing was co-led by Regeneron Ventures and Playground Global. Several new and exi...
29.07.2026How this 18-year-old’s love of origami helped him win a $100,000 at a science fairGrowing up on Japan's northernmost island allowed Hikaru Kuribayashi to immerse himself in nature, where origami patterns are everywhere. "Imagine a tiny ladybug," Kuribayashi, 18, told Business Insider. "That ladybug actuall...
27.07.2026TriNetX Appoints August Calhoun Chief Executive OfficerJeff Margolis Resumes Chairman Role as Company Completes CEO Transition CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- TriNetX, The Global Truth Engine for Better Human Health™ and operator of the world's leading federated health data netw...
22.07.2026This 16-year-old built an autonomous AI-powered robot turtle that finds microplastics in waterIn the summer of 2024, Evan Budz stood at the edge of his grandparents' pool in Canada, trying to solve a unique problem: How to make his autonomous sea turtle robot swim. "I remember some of my first tests. I would put my robot in the...
21.07.2026Telix Q2 Revenue US$247M, Strong Momentum and Pipeline ProgressMELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June ...
30.06.20265 Things to Know SCOTUS decisions, Dow at 52,000, the retirement savings gap and more in Morning SquawkThis is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Tuesday. As someone with protein coffee in their fridge, I can’t say I’m surprised that “functional beverages” are taking off. Stock fu...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In